Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Verastem Oncology

< Previous 1 2 3 Next >
Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer​
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
Tickers VSTM
Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
Tickers VSTM
New Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
From Verastem Oncology
Via Business Wire
Tickers VSTM
First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Strengthens Executive Leadership Team with Key Appointments
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology to Participate in Upcoming Investor Conferences
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer
From Verastem Oncology
Via Business Wire
Tickers VSTM
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.